Akamis Bio

Recent Finacing

Series A

Recent Raise

$60M

Akamis Bio is a clinical-stage oncology company developing IV-delivered T-SIGn® viral gene therapies that home to solid tumors and drive intratumoral expression of immunotherapeutic proteins like NG-350A.

Founded 2010

Oxfordshire, United Kingdom

11-50

Private

akamisbio.com

Highlights

Focus Areas

Biotechnology

Health Care

Oncology

Therapeutics

Recent Investors

Financials

$165.6M

Total Raised

5

Funding rounds

12

Investors

Team

Upgrade to view the team

See the team members at Akamis Bio.